OTCMKTS:MLLCF Molecular Partners (MLLCF) Stock Price, News & Analysis $5.89 0.00 (0.00%) (As of 09/10/2024 ET) Add Compare Share Share Today's Range$5.89▼$5.8950-Day Range$5.89▼$9.9052-Week Range$3.40▼$10.14VolumeN/AAverage Volume514 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartHeadlinesShort InterestStock AnalysisChartHeadlinesShort Interest Get Molecular Partners alerts: Email Address Ad Behind the MarketsHow you could collect “AI Royalties” from NVIDIA, META and TSMC...If you've missed out on the first wave of big AI winners... Don't worry. Because there's a much better - and potentially much more lucrative way - to play the $5 Trillion AI boom.Click here for the ticker >>> About Molecular Partners Stock (OTCMKTS:MLLCF)Molecular Partners AG operates as a clinical-stage biopharmaceutical company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317 which is in Phase I clinical trials, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia. It also develops Switch-DARPin platform, a multispecific cKIT x CD16a x CD47 Switch-DARPin program for targeted and conditional immune cell activation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has license and research collaboration agreements with Novartis AG to develop DARPin-conjugated radioligand therapies; and collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.Read More MLLCF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MLLCF Stock News HeadlinesAugust 10, 2024 | nz.finance.yahoo.comMolecular Partners AG (MLLCF)July 26, 2024 | msn.comWarner Bros. Discovery Partners With NYLFF, LALIFF to Fund Latino Content CreatorsSeptember 11, 2024 | Timothy Sykes (Ad)How to grow a small trading account into a $100k? Why is Warren Buffett dumping stocks? Billionaires like Warren Buffett, Tim Cook, and Jeff Bezos are offloading stocks at an incredible pace… But I’m not worried at all… Because I don’t hold stocks… Instead I trade in and out of them using a simple strategy that works in bull markets and bear markets. I’ll be breaking down this strategy in a free live broadcast on Thursday, September 12 at 6 PM ET, where I’ll also be giving away $100,000 in gifts to active attendees.April 30, 2024 | msn.comThe ‘Platonic Life Partners’ Raising a Baby in a Flatbush DuplexApril 30, 2024 | finance.yahoo.comECOPRO BM has taken a license from CAMX POWER to the latest GEMX® platform of cathode active material for lithium-ion batteriesApril 27, 2024 | msn.comIntermediate Capital Group snaps up leading legal business information provider for £650mApril 17, 2024 | finance.yahoo.comMolecular Partners Announces All Board Proposals Approved at the Annual General MeetingMarch 14, 2024 | msn.comMolecular Partners GAAP EPS of -$1.89 beats by $0.14, revenue of $7.0M beats by $1.93MSeptember 11, 2024 | Timothy Sykes (Ad)How to grow a small trading account into a $100k? Why is Warren Buffett dumping stocks? Billionaires like Warren Buffett, Tim Cook, and Jeff Bezos are offloading stocks at an incredible pace… But I’m not worried at all… Because I don’t hold stocks… Instead I trade in and out of them using a simple strategy that works in bull markets and bear markets. I’ll be breaking down this strategy in a free live broadcast on Thursday, September 12 at 6 PM ET, where I’ll also be giving away $100,000 in gifts to active attendees.March 12, 2024 | finance.yahoo.comExpert Systems Expands Partnership with Eilean Therapeutics and Joins Its Best-in-Class PTPN2 Inhibitor ProgramMarch 1, 2024 | marketwatch.comMolecular Partners Gets Investor Class Action TossedFebruary 9, 2024 | investing.comMolecular Partners AG (MOLN)February 7, 2024 | markets.businessinsider.comBuy Rating Affirmed for 4D Molecular Therapeutics on Promising Wet AMD Treatment Trial ResultsFebruary 6, 2024 | investing.comMolecular Partners AG ADR (MOLN)February 4, 2024 | msn.comScientists found a major clue why 4 of 5 autoimmune patients are womenFebruary 4, 2024 | msn.comPenn names new chief innovation officer, aiming to expand a multibillion-dollar windfall from faculty researchJanuary 5, 2024 | finance.yahoo.comMolecular Partners and Orano Med Announce Co-Development Agreement for Radio-DARPin TherapiesDecember 22, 2023 | finance.yahoo.comRetail investors account for 43% of Molecular Partners AG's (VTX:MOLN) ownership, while hedge funds account for 33%See More Headlines Receive MLLCF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Molecular Partners and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolOTCMKTS:MLLCF CUSIPN/A CIKN/A Webwww.molecularpartners.com Phone(144) 755-7700FaxN/AEmployees167Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesDr. Patrick Amstutz Ph.D. (Age 49)Co-Founder, CEO, Member of Management Board & Director Comp: $727.51kDr. Michael Tobias Stumpp Ph.D. (Age 52)Co-Founder, Executive VP of Projects & Member of Management Board Mr. Robert HendriksSenior VP of FinanceMr. Alexander Zurcher (Age 49)COO & Member of Management Board Ms. Renate Gloggner (Age 54)Executive VP of People & Community and Member of Management Board Mr. Daniel Steiner Ph.D.Senior Vice President of Research & TechnologyMr. Seth D. LewisSenior Vice President of Investor Relations, Communications & StrategyMr. Michael PitznerGeneral Counsel, Compliance Officer, Senior VP Legal & Business DevelopmentDr. Pamela A. Trail Ph.D. (Age 68)Strategic Consultant Ms. Anne Goubier D.V.M.Ph.D., Senior Vice President of Research & Early DevelopmentMore ExecutivesKey Competitors180 Life SciencesNASDAQ:ATNFW3SBioOTCMKTS:TRSBF60 Degrees PharmaceuticalsNASDAQ:SXTPWAbcamOTCMKTS:ABCZFAdociaOTCMKTS:ADOIFView All Competitors MLLCF Stock Analysis - Frequently Asked Questions How have MLLCF shares performed this year? Molecular Partners' stock was trading at $4.30 on January 1st, 2024. Since then, MLLCF shares have increased by 37.0% and is now trading at $5.89. View the best growth stocks for 2024 here. How do I buy shares of Molecular Partners? Shares of MLLCF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:MLLCF) was last updated on 9/11/2024 by MarketBeat.com Staff From Our PartnersFREE TRAINING TODAY ➡️ How to profit from 2024 electionEarlier this year, Millionaire Trader Nate Bear of Monument Traders Alliance went live in front of thousands o...Monument Traders Alliance | SponsoredHow to grow a small trading account into a $100k? Why is Warren Buffett dumping stocks? Billionaires like Warren Buffett, Tim Cook, and Jeff Bezos are offloa...Timothy Sykes | SponsoredKamala’s Promise Will Kill America (Revealed)Kamala’s 3-Word Plan to Destroy America — Are You Prepared? Discover the secret plan that will bankrupt eve...Banyan Hill Publishing | SponsoredWarning For Nvidia HoldersHow The Boeing Disasters Could Hit Nvidia Investors You may have heard about Boeing planes falling apart mi...Stansberry Research | SponsoredWall St. Icon: Looming Financial Tsunami will Wipe Out the 1%Wall Street icon who forecasted Black Monday and dot-com crash says a new economic event will hit the American...InvestorPlace | SponsoredThis Crypto Coin Could 10x FASTER Than BitcoinA shocking leak has revealed Japanese electronics giant Sony is now starting its own blockchain. This move ...Crypto 101 Media | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredIt’s over.We found a tiny company which provides the backbone for the entire $15.7 trillion AI industry... It's used ...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Molecular Partners AG Please log in to your account or sign up in order to add this asset to your watchlist. Share Molecular Partners With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MLLCF Stock Alerts